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OBJECTIVES: Renal cell carcinoma (RCC) is the most common renal tumor and
accounts for 2 to 3% of all adult malignancies. Up to 30% of patients with renal-cell
carcinoma present withmetastatic disease. The aim of the study was to assess the
cost-effectiveness of first-line medications for patients with metastatic RCC from
the payer‘s perspective.METHODS: A Markov model was developed using 6-week
cycles for evaluating the cost-effectiveness of fourmRCC first-line therapies: Inter-
feron- (3million units (MU)/day 3 times-per-week for first week; 6MU/day 3 times-
per-week for second week, 9MU/day 3 times per-week third week onward),
sunitinib (50mg/day 4 weeks ON  2 weeks OFF), sorafenib (400mg/twice-a-day)
and bevacizumab plus Interferon  (10mg/kg/bi-weekly  9MU 3 times-per-week
every 3weeks). Themodel had a 10-year time horizon. The fourmodel stageswere:
No progression, progression, best supportive care and death. Effectiveness data
were obtained through a systematic review, resource utilization were collected
from a Colombian Delphi Panel, and costs includedwere retrieved fromColombian
tariff manual (SOAT). Effectiveness was measured by progression-free life years
(PFLY) and life-years gained (LYG). Costs and outcomes were discounted with a 3%
annual rate. Univariate sensitivity analysis was developed. RESULTS: Sunitinib
showed higher overall mean costs per patient (US$ 5,215.48) compared to inter-
feron; while comparing against sorafenib and bevacizumab  interferon sunitinib
costs per patient revealed to be lower in US$12,946.01 and US$ 102,780.16 respec-
tively. Sunitinib had the higher effectiveness RESULTS: 1.35 PFLY, 2.9 LYG and 1.87
QALY. Incremental cost-effectiveness analysis shows sunitinib is cost-saving com-
pared to sorafenib and to the combination of bevacizumab  interferon, and com-
pared to monotherapy with interferon the incremental cost-effectiveness ratio
(ICER) per LYG for sunitinib was US$12,099, per PFLY was US$8,381 and per QALY
was US$14,901. CONCLUSIONS: This analysis indicates that sunitinib represents
the most cost-effective option for first-line mRCC treatment in Colombia.
PCN63
ADDITION OF BIVALENT OR QUADRIVALENT HPV VACCINES TO CERVICAL
CANCER SCREENING, IN COLOMBIA. A COST- EFFECTIVENESS ANALYSIS
Aponte J1, Eslava-Schmalbach J1, Gamboa O2, Fajardo L1
1Universidad Nacional de Colombia, Bogotá, Colombia, 2IECAS, Bogotá, Colombia
OBJECTIVES: To compare the costs and the effectiveness of three strategies against
Cervical Cancer (CC): (i) Screening for CC; (ii) Bivalent vaccine (BV) for HPV 16/18
along with screening and (iii) Quadrivalent Vaccine (QV) for HPV 6/11/16/18 along
with screening. METHODS: A Markov model was designed to simulate natural
history of disease in women, since 12 –vaccination-until 85 years old. Transition
probabilities were selected or adjusted to correspond to HPV distribution profile
amongColombianwomen.A systematic reviewwas performed to obtain efficacy of
vaccines and screening. Societal perspective was used. The costs analysis included
medical and non-medical such as transport, patient/ companion time and care at
home. Effectiveness was measured in number of life years saved (LYS). Since QV
protects againstHPV 6/11which causedGenitalWarts, the impact of this additional
effect is measured in the saved money by the reduction in treatment of GW cases.
RESULTS: BV was found to be the most costly and also the most effective strategy,
followed by QV and finally screening alone. QV resulted to have an incremental
cost- effectiveness ratio of US 2232 per LYS; BV compared with QV had an incre-
mental cost-effectiveness ratio of US 7335. Per 100.000 women vaccinated with QV,
8252 LYS are gained over screening alone. For BV only 348 LYSwere gained over QV.
According to sensibility analysis, results were not affected by vaccines effective-
ness but changes in current price of them could modify cost-effectiveness profile.
With a 12% price reduction, BV dominate over quadrivalent vaccine.
CONCLUSIONS: Both vaccines resulted to be similar in costs an also in effective-
ness for Colombian context. HPV vaccination is farmore effective but also farmore
expensive than screening. HPV vaccination is recommended in Colombia but price
considerations should be taken into account.
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THE COST EFFECTIVENESS OF CETUXIMAB PLUS BEST SUPPORTIVE CARE (BSC)
VERSUS BSC ALONE IN LAST LINE FOR KRAS WILD TYPE METASTATIC
COLORECTAL CANCER PATIENT POPULATION
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University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Cetuximab, a chimeric monoclonal antibody, improved the overall
survival and progression free survival of chemorefractory metastatic colorectal
cancer (mCRC) KRAS wild (unmutated) type patients in the National Cancer Insti-
tute of Canada Clinical Trials Group (NCIC CTG) CO.17 study. The objective of our
study was to conduct the cost-effectiveness analysis of cetuximab plus best sup-
portive care versus best supportive care alone in KRAS wild type mCRC patients.
METHODS: AMarkov cohort simulation model was used to simulate therapy costs
and effectiveness from the US societal perspective. All estimates of costs and ef-
fectiveness were obtained from the literature. The cost-effectiveness ratio was
reported as incremental cost per quality-adjusted life-year (QALY) gained. A life
time horizon was used. Base case costs and QALYs were discounted at an annual
rate of 3%. All costs were adjusted to 2011 US dollars. One-way and probabilistic
sensitivity analyses were used to determine the robustness of the model’s results
using @Risk. Themodel was developed using Microsoft Excel. RESULTS: The incre-
mental cost with cetuximab comparedwith best supportive care alonewas $93,934
and the mean gains in quality adjusted survival were 0.30 QALYS. This resulted in
base case ICER of $313,113 perQALY gained. The resultswere highly sensitive to the
cost of cetuximab and health state utility values. CONCLUSIONS: The incremental
cost effectiveness ratio of $313,113 per QALY gained for cetuximab plus BSC com-
pared with BSC alone suggests that cetuximab is not cost effective in KRAS wild
type patients with metastatic colorectal cancer even with a willingness-to-pay
cut-off threshold of $120-$150,000 per QALY gained.
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OBJECTIVES: To describe outcomes and economic impact of hypomethylating
therapy (Decitabine/Azacitidine) compared to transfusion therapy in adult patients
with Myelodysplastic syndrome (MDS) non-candidates to transplant. METHODS:
Was building a Markov Model simulating the disease with 6 stages; Myelodysplas-
tic syndrome in treatment, Complete PartialHematologic Response (CPHR),
transfusion independent, transfusion dependent, Myeloid Leukemia and Death.
Every medication was compared with each control group in two different simula-
tions because the characteristics of every control group were different. We were
interested in finding the incremental values in outcomes and costs of each treat-
ment. Our case base was an adult patient with MDS non-candidate to transplant.
The Temporal Horizon was 1 year, perspective of insurer and mortality avoided
progression free disease (PFD) and survival as outcomes. The statistics inputs of the
model for the transitions were the Kapplan-Meier curves of Kantarjian H and Fe-
naux P papers. Were used direct costs from a private hospital in Bogota, Colombia
and government prices according regulation laws. RESULTS: The simulation proj-
ect incremental effectiveness for both hypometilants compared with transfu-
sion therapy. In terms of CPHR was 40% for Decitabine and 28% for Azaciti-
dine, in PFD was 73% for Decitabine and 76% for Azacitidine and survival was
50% for Decitabine and 37% for Azacitidine. Compared with transfusion therapy
Decitabine was a cost-saving alternative (better results with lower costs) vs.
cost-effectiveness for Azacitidine (better results with higher costs).
CONCLUSIONS: In Colombia the hypomethylant therapy with Decitabine is a cost-
saving alternative compared with transfusion therapy.
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ECONOMIC EVALUATION OF ABIRATERONE ACETATE AS TREATMENT FOR
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DOCETAXEL IN SWEDEN
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OBJECTIVES:Abiraterone acetate (AA), a selective androgen biosynthesis inhibitor,
blocks the action of CYP17, thereby inhibiting adrenal and intratumoral androgen
synthesis. In a preplanned interim analysis of the Phase 3 trial COU-AA-301, AA
plus prednisone (P) showed a significant overall survival (OS) benefit of 3.9 months
vs placebo plus P (de Bono, NEJM 2011). A preplanned and updated analysis showed
that the improvement in median OS increased from 3.9 months to 4.6 months
(HR  0.74) (Scher, ASCO 2011). The purpose of this study was to evaluate the
cost-effectiveness of AA compared to cabazitaxel. METHODS: A survival-based
decision analysis model was developed incorporating 3 health states: progression-
free survival, post-progression survival, and OS (indirect comparison). Assuming
mitoxantrone (M)  P versus P equivalence, a cost-effectiveness model was popu-
latedwith data from two placebo-controlled randomized clinical trials inwhich: (1)
AAwas an add-on to P (de Bono, NEJM 2011), and 2) cabazitaxel or Mwas an add-on
to P (de Bono, Lancet 2010) in patients with metastatic castrate-resistant prostate
cancer post-docetaxel. Resource utilization and costs reflected Swedish treatment
conditions within a broad societal perspective. Drug costs per 3-week-model-cycle
were $3180 (€2300) and $6730 (€4860) for AA and cabazitaxel, respectively.
RESULTS: Total costs per patient were $103,100 (€74,400) and $104,600 (€75,500) for
AA and cabazitaxel, respectively. Quality-adjusted life years (QALYs) were 0.94 and
0.83 for AA and cabazitaxel, respectively. CONCLUSIONS: The results show that AA
treatment is superior to cabazitaxel in cost per QALY gained. AA appears to provide
an OS benefit, compared to cabazitaxel, with a highly manageable and benign
safety profile. Adverse events affect both costs associated with taking a given drug
as well as health-related quality-of-life of patients receiving treatment.
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COST EFFECTIVENESS OF ZOLEDRONIC ACID (ZOL) IN POSTMENOPAUSAL
WOMEN WITH EARLY BREAST CANCER RECEIVING ADJUVANT LETROZOLE
FROM GERMAN AND ITALIAN PERSPECTIVES
Xue M1, Fishman P2, Botteman M1
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OBJECTIVES: In the ZO-FAST trial, postmenopausal women with early breast can-
cer (pmBCa) and a bonemineral density (BMD) T-score–2 and receiving adjuvant
Letrozole (2.5 mg/day) were randomized to either immediate ZOL (4 mg/6 months)
treatment (“Upfront ZOL”) or to the same therapy but only when BMD T-score
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decreased to2 or fracture occurrence (“Delayed ZOL”). After 60months, Upfront
ZOL increased both BMD and disease-free survival (P.05) relative to Delayed ZOL.
The present analysis assessed the cost effectiveness of Upfront vs. Delayed ZOL in
this population, fromGerman (DE) and Italian (IT) payer perspectives.METHODS:A
Markov state-transition model was constructed to estimate the lifetime costs and
QALY for hypothetical cohorts of pmBCa women receiving Letrozole with Upfront
or Delayed ZOL. Consistent with ZO-FAST, at baseline, patients were 57 years old
and BCa-recurrence free. Patients could progress over time to “Local Recurrence”,
“Contralateral Tumor”, “Distant Recurrence”, or Death. Annual transition probabil-
ities were derived from ZO-FAST, supplemented with literature estimates. Direct
costs and utilitieswere literature-based. All resultswere discounted using country-
specific rates. RESULTS: In IT, Upfront ZOL treatment was associated with 15.01
QALYs and €21 998. Delayed ZOLwas associated with 13.98 QALYs and €19 458. Thus,
Upfront ZOL cost €2 453/QALY. In DE, Upfront ZOL treatment resulted in 15.44 QALYs
and €24 032. Delayed ZOL was associated with 14.37 QALYs and €23 081. Therefore,
Upfront ZOL cost €888/QALY. In both countries, the results were very insensitive to
changes in individual model input values. Compared to Delayed ZOL, Upfront ZOL
treatment cost€20000/QALY in95%of 1000probabilistic sensitivity analysismodel
runs in both IT and DE. CONCLUSIONS: This analysis suggests that treatment with
Upfront ZOLmay reduce recurrence and increase QALY and is highly cost effective
relative to a Delayed ZOL strategy from an IT and DE health care perspective.
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COST-EFFECTIVENESS OF HER-2-POSITIVE METASTATIC-BREAST-CANCER
TREATMENT IN POST-HERCEPTIN PROGRESSION IN COLOMBIA
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OBJECTIVES: Breast Cancer (BC) is the first cause of death among women, and it
progresses to metastatic breast cancer (MBC) in half of the cases. HER-2 overex-
pression is a marker of the worst prognosis and the target of guided therapies. The
aim of this study is to assess the cost-effectiveness of therapies against BC with
overexpressed HER-2 in Colombia. METHODS: A cost-effectiveness study of MBC
treatment in HER-2-positive patients progressing to Trastuzumab was conducted,
with a 5-year horizon. Lapatinib  Capecitabine was compared to Herceptin 
chemotherapy (Capecitabine, Vinorelbine or a Taxane). The effectiveness rates of
those therapies were identified based on published primary studies. In the absence
of head-to-head comparisons, Weibull functions for each chemotherapy were es-
timated from the survival curves and were multiplied by their hazard ratios. The
perspective was that of the third payer including all direct medical costs based on
Standard National Tariffs. Finally, a Markov model was developed, incremental
cost-effectiveness ratios, (ICER), sensitivity analysis, and acceptability curve were
estimated. The discount rate used was 3%. RESULTS: Lapatinib  Capecitabine
(LC) is the most effective and less expensive alternative. Hence, it overcomes the
alternatives. The cost-effectiveness ratio of such strategy is Col$49 725 045 per year
of life gained. CONCLUSIONS: The strategy with lapatinib is cost-effective in the
treatment of MBC after progression to Herceptin.
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COST-EFFECTIVENESS ANALYSIS OF AROMATASE INHIBITORS AND
TAMOXIFEN AS AN ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH
EARLY-STAGE HORMONE RECEPTOR POSITIVE BREAST CANCER
Sura SD, Sansgiry SS
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OBJECTIVES: The objective of this study was to estimate the cost-effectiveness of
Aromatase Inhibitors (AIs) (anastrozole, letrozole and exemastane) and tamoxifen
as adjuvant treatment of postmenopausal women with hormone receptor positive
early breast cancer. METHODS: A Markov model comprising of five health states
(on treatment, local recurrence, distant cancer, die due to breast cancer and die due
to other causes) was developed to estimate the incremental cost per quality ad-
justed life-year (QALY) gained for anastrozole, letrozole, exemestane and tamox-
ifen. The analysis was carried out from a third party payer perspective. Transition
probabilitieswere estimated based on randomized clinical trials. Drug costs, health
utilities, and direct and indirect costs were obtained from published literature. The
timehorizonusedwas 25 years for the hypothetical cohort of 1000 postmenopausal
women with hormone receptor positive breast cancer. Costs and QALY were dis-
counted by 5% annually. Sensitivity analyseswere performed by varying the values
of key parameters, QALY and costs. RESULTS: Under base case assumptions, more
QALYs per patient would be gained with letrozole (4.6) than with anastrozole (3.6),
exemestane (3.6) and tamoxifen (3.3). The cost of gaining one QALY with letrozole
was $42,307 compared with exemestane ($71,081), tamoxifen ($76,826) and anas-
trozole ($ 78,114). The estimated ICER of letrozole, exemestane and anastrozole
compared with tamoxifen was -$47,560, $9,828 and $93,513 respectively. These
resultswere robust to the two-way sensitivity analyses performed.CONCLUSIONS:
In our analysis, letrozole was the cost-effective treatment compared to anastro-
zole, exemestane and tamoxifen for the primary adjuvant treatment postmeno-
pausal women with hormone receptor positive early-stage breast cancer. Instead
of comparing only monotherapy for cost-effectiveness, future research should
consider combination therapy while allowing switching between drugs.
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OBJECTIVES: To develop a cost-effectiveness analysis based on PFS of pazopanib
versus sunitinib in the treatment of aRCC in the Mexican context.METHODS: First
an adjusted indirect comparison was calculated between pazopanib versus inter-
feron (IFN) and pazopanib versus sunitinib. The hazard ratio (HR) of pazopanib
versus BSCwas obtained from the IRC subanalysis based on scan dates for patients
who progressed; same for sunitinib versus IFN. The HR of IFN versus BSC was
obtained from the MRCRCC study. A Markov model comparing pazopanib versus
sunitinib was designed with a two years time horizon and with a 5% discount in
costs and effectiveness. The costs of drugs and adverse events (AE) grades III and IV
were included for both alternatives.We did a probabilistic sensitivity analysis (PFS)
with 1,000 simulations. Exchange rate: 1USD  13.6MXN. RESULTS: The adjusted
indirect comparison yield a HR for pazopanib versus IFN of 0.545(95% CI, 0.341-
0.871) and for pazopanib vs. sunitinib of 1.012(95% CI, 0.613-1.670). The cost-effec-
tiveness analysis showed a reduction in average cost per patient of $8171 and a
reduction of 1.15 days PFSwhenusing pazopanib compared to sunitinib; incremen-
tal cost-effectiveness ratio (ICER) of $2,525,515 per PFS year (Mexican threshold is
$13,900). According to the PSA 0.7% cases were more effective at a higher cost,
47.4% cases were more effective at a lower cost and 51.9% cases were less effective
at a lower cost comparedwith sunitinib. TheAEs cost analysis showed that the cost
of treating AEs of sunitinib was $982(95% CI, $788-$1,112) and for pazopanib was
$137(95% CI, $87-$192). CONCLUSIONS: Based on PFS time pazopanib demon-
strated to be an equivalent alternative to sunitinib in the treatment of aRCC.
Sunitinib had an ICER considerably above the Mexican threshold. Pazopanib
showed a different toxicity profile that was considerably less costly compared to
sunitinib.
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COST EFFECTIVENESS ANALYSIS OF BUSULFAN  CYCLOPHOSPHAMIDE
(BUCY2) AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HUMAN STEAM
CELL TRANSPLANTATION (HSCT): COMPARISON OF ORAL VERSUS IV
BUSULFAN
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HSCT is used as the treatment of hematologic malignancies and BuCy2 is a condi-
tioning regimen before HSCT but is associated to high rates of hepatic veno-occlu-
sive disease (HVOD) mainly due to busulfan (oralBu) plasma concentration vari-
ability after oral administration. Intravenous busulfan (IVBu) shows constant
plasma concentration allowing better targeting of plasma exposure and reducing
occurrence of HVOD. OBJECTIVES: Develop an economic model based in Mexican
Institute of Social Security (IMSS) resource payments to evaluate the cost-effective-
ness of oralBu versus IVBu as conditioning regimen before HSCT in Mexico.
METHODS: A two branch decision tree model in patients with 40 or 60 kg of weight
was developed to evaluate the cost-effectiveness in Mexican pesos (MxP) of IVBu
(0.8mg/Kg/6hrs) or OralBu (1mg/Kg/6hrs) combined with intravenous cyclophos-
phamide (60mg/kg/tid) as conditioning regimen before HSCT. The effectiveness
measure was HVOD non-occurrence obtained from published clinical trials. Re-
source use and costwere obtained froman expert panel survey and IMSS published
data. The model estimated non discounted cost per patient and incremental cost-
effectiveness ratios. Probabilistic sensitivity analysis was performed using Monte
Carlo simulation second-order approach and deterministic analysis. RESULTS:
HVOD non-occurrence was 84.88% in IVBu group and 51.34% in oralBu group. Cost
per patient was lower with IVBu ($148,712.19 - $180,562.79 MxP) than OralBu
($291,088.60 to $293,296.88 MxP) showing that IVBu was the dominant alternative.
Sensitivity analysis showed model robustness and confirm IVBu as dominant.
CONCLUSIONS: IVBu is a cost-effective conditioning regimen inMexico and should
be considered by clinicians and decision makers as a favorable option before Allo-
geneic HSCT.
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CASTRATION-RESISTANT PROSTATE CANCER: DOES SEVERITY MATTER?
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OBJECTIVES: To evaluate cost-effectiveness of abiraterone and cabazitaxel com-
pared to existing palliative chemotherapy, mitoxantrone and placebo for meta-
static castration-resistant prostate cancer (mCRPC) patients; focusing on differ-
ences in baseline illness severity. METHODS: A decision tree comparing four
treatment strategies in mCRPC patients over an 18-month-period was constructed
from the societal perspective. Chance nodes included baseline pain as a severity
indicator, grade III & IV neutropenia or cardiac events, and survival at 18 months.
Probabilities and life expectancies were from two clinical trials (COU-AA1 and
TROPIC2). Costs in 2010 US dollars included drugs (Redbook), physician visits, pro-
cedures, tests (CPT-codes) and hospitalizations (HCUP). Model cost inputs included
drugs, chemotherapy administration, adverse events management, radiotherapy
for pain palliation, and death. The short duration excluded need for discounting.
Utilities for bone pain, neutropenia, cardiac events and radiation therapy were
from published sources. Baseline severity was altered to reflect relatively ill
populations. RESULTS: Cabazitaxel and abiraterone give the best effects and caba-
zitaxel ismost costly. Formitoxantrone as comparedwith placebo, the incremental
cost effectiveness ratio (ICER) was $110K/QALYS and $63K/LYS. For abiraterone
versus mitoxantrone, the ICER was $76K/QALYS and $52K/LYS. Cabazitaxel has an
ICER of $925K/QALYS and $378K/LYS compared to abiraterone. One-way and prob-
abilistic sensitivity analyses show a robust model for most variables. This re-
mained so across the majority of WTP thresholds shown in acceptability curves
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